Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07939750
PHASE4

Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes

Sponsor: Allied Hospital Faisalabad

View on ClinicalTrials.gov

Summary

The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.

Official title: Comparison of the Effect of Metformin-Sotagliflozin Versus Metformin-Empagliflozin Combination Therapy on Glycemic Control Measured by HbA1c in Patients With Type 2 Diabetes Mellitus

Key Details

Gender

All

Age Range

30 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

140

Start Date

2026-12-01

Completion Date

2028-01-31

Last Updated

2026-11-16

Healthy Volunteers

No

Interventions

DRUG

Sotagliflozin

200 mg tablet orally once daily for 24 weeks

DRUG

Empagliflozin (oral)

10 mg tablet orally once daily for 24 weeks

DRUG

Metformin

continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated)

Locations (1)

Allied Hospital, Faisalabad Medical University

Faisalabad, Punjab Province, Pakistan